α6-integrin

Hexapeptide-10 Acetate (Hexapeptide-10 Acetate) is a synthetic peptide. It increases the synthesis of laminin V and α6-integrin to promote cell binding, with extraordinary visible skin restructuring and firming abilities.

Integrin-IN-2 is an orally bioavailable pan αv integrin inhibitor.Integrin-IN-2 can increases the αvβ6, αvβ3, αvβ5 and αvβ8 binding affinities with pIC50 values of 7.8, 8.4, 8.4 and 7.4, respectively.

GSK 3008348 hydrochloride is an αvβ6 integrin inhibitor used to confirm idiopathic pulmonary fibrosis.

MK-0429 is an orally active, selective, and nonpeptide antagonist of αvβ3 integrin (IC50: 80 nM).

αvβ6-IN-2 (compound 20) is an effective orally active inhibitor of αvβ6 integrin (αvβ6integrin), with a pIC50 value of 7.8. It shows potential for use in research on idiopathic pulmonary fibrosis.

αvβ6-IN-1 (compound 28) is an effective orally active inhibitor of αvβ6 integrin (αvβ6integrin), with a pIC50 value of 8.1. This compound shows potential for research in idiopathic pulmonary fibrosis.

MORF-627 is an orally active selective inhibitor of integrin αvβ6 (integrinαvβ6), with an IC50 of 9.2 nM as measured in a human serum ligand binding assay. It effectively inhibits αvβ6-mediated activation of TGF-β1 with an IC50 of 2.63 nM and suppresses SMAD2/3 phosphorylation, showing an IC50 of 8.3 nM. Additionally, MORF-627 ameliorates bleomycin-induced pulmonary fibrosis in mice.

Bexotegrast (PLN-74809) is an orally active and potent inhibitor of αvβ6 and αvβ1 integrins with antifibrotic effects, inhibiting αvβ6 and αvβ1-induced activation of TGF-β. It is applicable for studies of idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP).

EMD527040 is a powerful and highly specific αvβ6 antagonist, exhibiting notable antifibrotic properties. It is suitable for conducting research on carcinoma and liver fibrosis.

αvβ6 Integrin Inhibitor 2 is a potent inhibitor of αvβ6 integrin, demonstrating an inhibition concentration (IC50) of 96.5 nM.

STX-100 is a humanized antibody targeting integrin αvβ6 (ITGAV & ITGB6) with anti-tumor activity, inhibits pSMAD2, inhibits the conversion of fibroblasts to myofibroblasts, and can be used to study idiopathic pulmonary fibrosis (IPF).

CWHM-12 is a potent inhibitor of αV integrins, with IC50 values of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1, respectively.

Hexapeptide-10 is a synthetic peptide. It increases the synthesis of laminin V and α6-integrin to promote cell binding, with extraordinary visible skin restructuring and firming abilities.